Norden Group LLC Argenx Se Transaction History

Norden Group LLC

$847 Billion
Q3 2024

A detailed history of Norden Group LLC transactions in Argenx Se stock. As of the latest transaction made, Norden Group LLC holds 496 shares of ARGX stock, worth $311,646. This represents 0.03% of its overall portfolio holdings.

Number of Shares

496

Holding current value

$311,646

% of portfolio

0.03%

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q3 2024 Oct 17, 2024	BUY	$434.22 - $551.9 $215,373 - $273,742	496 New	496 $269 Million
Q1 2024 Apr 19, 2024	BUY	$356.95 - $413.29 $1.33 Million - $1.54 Million	3,720 New	3,720 $1.46 Billion

Others Institutions Holding ARGX

# of Institutions

400

Shares Held

30.9M

Call Options Held

376K

Put Options Held

489K

Price T Rowe Associates Inc Baltimore, MD

5.82M
Shares

$3.66 Billion
0.36% of portfolio
Artisan Partners Limited Partnership Milwaukee, WI

3.51M
Shares

$2.21 Billion
2.99% of portfolio
Janus Henderson Group PLC London, X0

2.48M
Shares

$1.56 Billion
0.72% of portfolio
Capital World Investors Los Angeles, CA

1.7M
Shares

$1.07 Billion
0.15% of portfolio
Avoro Capital Advisors LLC New York, NY

1.24M
Shares

$778 Million
10.11% of portfolio

View Full List

About ARGENX SE

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $34.8B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

More about ARGX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Norden Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Norden Group LLC with notifications on news.

Account